Results 251 to 259 of about 96,322 (259)

Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study)

Annals of Oncology, 2016
Kengo Takeuchi, Naoyuki Nogami, T Hida
exaly  

ALK-rearrangement in non-small-cell lung cancer (NSCLC)

Thoracic Cancer, 2018
Xue Du
exaly  

Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells

Oncogene, 2004
Estelle Espinos, Christian Touriol
exaly  

Anaplastic Lymphoma Kinase (ALK) Receptor Tyrosine Kinase: A Catalytic Receptor with Many Faces

International Journal of Molecular Sciences, 2018
Hao Huang
exaly  

Immunohistochemistry as a screening tool for ALK rearrangement in NSCLC: evaluation of five different ALK antibody clones and ALK FISH

Histopathology, 2014
Cornelia Hauser-Kronberger, Ida C Llenos, Otto Dietze   +2 more
exaly  

Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma

Annals of Oncology, 2012
Marius Ilié, Paul Hofman, HOFMAN veronique   +2 more
exaly  

Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study

Journal of Thoracic Oncology, 2019
Denis Moro-Sibilot, Rafal Dziadziuszko, Solange Peters   +2 more
exaly  

Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma

Annals of Oncology, 2013
exaly  

Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance

Cancer Letters, 2014
exaly